

7<sup>TH</sup> EDITION

**PHARMACOLOGY**  
**AND THERAPEUTICS**  
**FOR DENTISTRY**

DOWD  
JOHNSON  
MARIOTTI

[DowdPharmacologyForDentistry.com](http://DowdPharmacologyForDentistry.com)

ELSEVIER

**7**TH EDITION

# PHARMACOLOGY AND THERAPEUTICS FOR DENTISTRY

**FRANK J.  
DOWD, DDS, PhD**

Professor Emeritus  
Pharmacology  
Creighton University, School of  
Medicine and School of Dentistry  
Omaha, Nebraska

**BARTON S.  
JOHNSON, DDS, MS**

Director, General Practice Residency  
Program  
Swedish Medical Center  
Private Practice  
Seattle Special Care Dentistry  
Seattle, Washington

**ANGELO J.  
MARIOTTI, DDS, PhD**

Professor and Chair  
Periodontology  
The Ohio State University  
Columbus, Ohio

ELSEVIER

# ELSEVIER

3251 Riverport Lane  
St. Louis, Missouri 63043

PHARMACOLOGY AND THERAPEUTICS FOR DENTISTRY,  
SEVENTH EDITION

ISBN: 978-0-323-39307-2

**Copyright © 2017 Elsevier, Inc. All rights reserved.**

Previous editions copyrighted 2011, 2004, 1998, 1985, 1980 by Mosby, Inc., an affiliate of Elsevier, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

## Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

## Library of Congress Cataloging-in-Publication Data

Names: Dowd, Frank J., 1939- editor. | Johnson, Barton S., editor. | Mariotti, Angelo J., editor.  
Title: Pharmacology and therapeutics for dentistry / [edited by] Frank J. Dowd, Barton S. Johnson, Angelo J. Mariotti.  
Description: 7th edition. | St. Louis, Missouri : Elsevier, Inc., [2017] | Includes bibliographical references and index.  
Identifiers: LCCN 2016020799 | ISBN 9780323393072 (hardback : alk. paper) | ISBN 9780323445955 (e-book)  
Subjects: | MESH: Pharmacological Phenomena | Dentistry | Pharmaceutical Preparations | Pharmaceutical Preparations, Dental | Drug-Related Side Effects and Adverse Reactions  
Classification: LCC RM300 | NLM QV 50 | DDC 615.102/46176--dc23 LC record available at <https://lccn.loc.gov/2016020799>

*Executive Content Strategist:* Kathy Falk  
*Content Development Manager:* Jolynn Gower  
*Associate Content Development Specialist:* Laura Klein  
*Publishing Services Manager:* Deepthi Unni  
*Project Manager:* Kamatchi Madhavan  
*Book Designer:* Brian Salisbury

Printed in United States of America.

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

## REMEMBERING JOHN A. YAGIELA, DDS, PhD, AND ENID A. NEIDLE, PhD

Since the publishing of our last edition (6th) of this textbook, we have lost two of our former editors, dear friends, and true giants in the field of dental education: John A. Yagiela and Enid A. Neidle. Both had been editors through all of the previous editions of this textbook, and both were very instrumental in providing the initial focus and establishing its content. This is the first time since 1980 that the names of these two outstanding individuals will not appear on the book as editors. John and Enid have left a lasting legacy. We dedicate this edition to their memory as we carry on the tradition of providing a current and thorough treatment of pharmacology for dental students and the dental profession.

John Allen Yagiela was born in Washington, DC, but grew up in Los Angeles.



He received his dental degree from UCLA in 1971 and his PhD in pharmacology from the University of Utah in 1975 and completed a residency in anesthesiology from the UCLA School of Medicine in 1983. Dr. Yagiela used his expertise in pharmacology and anesthesiology to make this textbook the standard reference for all dental students. His contributions to critical chapters in principles of pharmacology and dental anesthesia were immensely important for the foundation of basic pharmacologic principles for dental students and professionals. Moreover, as the lead editor, he was tireless in his effort to make certain all chapters were accurate and current. John applied his vast knowledge and abundant energy to all the things that are required to insure a quality textbook. He was always helpful to contributors and often helped authors who needed assistance with certain aspects of their chapters. This included everything from providing expert advice on the text, to providing figures to authors, down to simply explaining when to correctly use a dash. We always found him supportive and willing to provide information and advice on many areas of pharmacology. The field of dental anesthesiology and dental education in general, as well as this text, will be forever in his debt. John was active as a clinician in the area of dental anesthesiology. Indeed, he was a key and devoted advocate for the field of dental anesthesiology and was largely responsible for spearheading the recognition of anesthesiology as a

specialty of dentistry. John spent the majority of his academic carrier at UCLA School of Dentistry where he held several leadership positions, including professor (later Professor Emeritus) and Chair, Department of Diagnostic and Surgical Sciences. He was also in demand as a keynote speaker and has received many academic awards. On a personal note, he was a kind, fun, and an ever-inquisitive man who delighted in the wonders of the universe.

Enid Anne Neidle received her PhD from the Department of Physiology at Columbia University.



Her first faculty position was in the Department of Pharmacology at the Jefferson Medical College in 1950, but she moved to New York University in 1955 to become an Instructor in the Department of Physiology, which began a long career in the College of Dentistry. Dr. Neidle was the initial force behind this text and has had a key role in the previous editions. It was her insight that brought to fruition the first thorough textbook of pharmacology and therapeutics designed for the dental profession. As the textbook's first lead editor, she was dedicated to finding key people to contribute to the text and deciding on its focus to better serve the dental community. She was also a major contributor to dental education. Dr. Neidle was professor (later Professor Emeritus) and Chair, Department of Pharmacology, New York University School of Dentistry. Her initial research contributed to the field of cholinergic and anticholinergic drugs and later to dental education. She spent 33 years of her career at New York University, and she held several positions in organized dentistry, including Assistant Executive Director of Scientific Affairs for the America Dental Association for 6.5 years. One of her passions was to further the cause of women in dentistry. She received several honors for her work and dedication, including a national scholarship named in her honor. Enid was also in demand as a public speaker and was an early advocate of evidence-based dentistry. Those of us who knew her from the first edition of this textbook remember Enid for her abundant organizational skills and devotion to academic dentistry. (From those early years on, I found her most supportive and instructive. – FD)

## **HONORING BART JOHNSON, DDS, MS**

---

We are deeply saddened by the recent passing of Bart Johnson, one of the three editors of this textbook. Bart was an editor not only of this edition but also the sixth edition as well as an author over the previous three editions. In 2015, Dr. Johnson was diagnosed with stage 4 colon cancer. Nonetheless, he remained an editor until this edition was finished.

Barton Johnson received his DDS degree in 1985 from UCLA. He continued on at UCLA in a general practice residency, and later earned an MS degree in Oral Biology. He was a faculty member at the University of Washington School of Dentistry from 1991 to 2007, and directed its General Practice Residency program during that time. Bart held many prominent leadership positions including President of the American Association of Hospital Dentists. He had been Director of the Swedish General Practice Residency from 2009 to 2016. Dr. Johnson

specialized in special care dentistry, serving the needs of patients with significant underlying medical issues. He also contributed his knowledge and experience as editor and author. His expertise included pharmacology, internal medicine, medical emergencies, hospital dentistry, and basic and advanced cardiac life support.

We deeply appreciate all the wonderful work he did with the book, especially with the battle he had and with his extensive clinical responsibilities. He made several critical editorial contributions to the book. He was a trusted colleague who offered expert advice, and is the sole author of two chapters in the book. We are all grateful and proud of his many contributions to dental pharmacology. It has been a joy to work with Bart and to witness his courage and positive attitude while dealing with his disease. We appreciate his dedication to the book and his professionalism even when it was a special challenge.

It is with the utmost respect and gratitude that we honor Bart.

# ABOUT THE EDITORS



## **FRANK J. DOWD**

---

Frank J. Dowd is Professor Emeritus, Creighton University School of Medicine and School of Dentistry. He received his DDS degree from Creighton University School of Dentistry and his PhD degree in pharmacology from Baylor College of Medicine. He spent his professional career at Creighton University, most of it as Chair, Department of Pharmacology, School of Medicine.



## **BARTON S. JOHNSON**

---

Barton S. Johnson received his DDS, GPR Certificate, and MS in oral biology (with a molecular biology focus) from UCLA. His career has focused on the dental care of high-risk medically, mentally, emotionally, and physically challenged people. He was, until his passing, the Director of the Swedish Medical Center GPR program in Seattle.



## **ANGELO J. MARIOTTI**

---

Angelo J. Mariotti graduated from Grove City College with a BS in biology and education and received his PhD in pharmacology/toxicology and DDS from West Virginia University as well as specialty training in periodontology from Virginia Commonwealth University. He currently serves as Professor and Chair of Periodontology at The Ohio State University.

# CONTRIBUTORS

**Peter W. Abel, PhD**

Professor  
Department of Pharmacology  
Creighton University School of Medicine  
Omaha, Nebraska

**Marc-Alain Babi, MD**

Neurocritical Care Fellow  
Department of Neurology  
Duke University Hospital  
Durham, North Carolina

**Jeffrey D. Bennett, DMD**

Professor and Chair  
Department of Oral Surgery and Hospital  
Dentistry  
School of Dentistry  
Indiana University  
Indianapolis, Indiana

**Charles S. Bockman, PhD**

Assistant Professor  
Department of Pharmacology  
Creighton University School of Medicine  
Omaha, Nebraska

**James T. Boyd, MD**

Associate Professor  
Department of Neurological Sciences  
University of Vermont  
Burlington, Vermont

**George A. Cook, PhD**

Professor  
Department of Pharmacology  
University of Tennessee  
Health Science Center  
Memphis, Tennessee

**Matthew R. Cooke, DDS, MD, MPH**

Assistant Professor  
Department of Dental Anesthesiology  
School of Dental Medicine  
Pittsburgh University  
Pittsburgh, Pennsylvania

**Xi-Qin Ding, PhD**

Associate Professor  
Department of Cell Biology  
College of Medicine  
University of Oklahoma Health Sciences  
Center  
Oklahoma City, Oklahoma

**Raymond A. Dionne, DDS, PhD**

Research Professor  
Department of Pharmacology and  
Toxicology  
Brody School of Medicine at East Carolina  
University  
Greenville, North Carolina

**Clayton English, PharmD**

Associate Professor  
Department of Pharmacology Practice  
Albany College of Pharmacy and Health  
Sciences  
Colchester, Vermont  
Psychiatric Pharmacist  
University of Vermont  
Medical Center  
Burlington, Vermont  
Adjunct Assistant Professor  
Department of Psychiatry  
University of Vermont  
Burlington, Vermont

**Sean Flynn, PhD**

Assistant Professor  
Department of Neurological Sciences  
University of Vermont  
Burlington, Vermont

**Gail T. Galasko, PhD**

Professor and Pharmacology Course  
Director  
Department of Biomedical Sciences  
College of Medicine  
Florida State University  
Tallahassee, Florida

**Steven I. Ganzberg, DMD, MS**

Clinical Professor of Anesthesiology  
UCLA School of Dentistry  
Los Angeles, California  
Editor-in-Chief, Anesthesia Progress

**James N. Gibson, PharmD**

Clinical Pharmacist-Hematology/Oncology  
University of Washington Medical Center  
Seattle Cancer Care Alliance  
Seattle, Washington  
Clinical Instructor  
University of Washington  
School of Pharmacy  
Seattle, Washington

**Joseph A. Giovannitti Jr., DMD**

Professor and Chair  
Department of Dental Anesthesiology  
Director of Anesthesia  
Center for Patients with Special Needs  
University of Pittsburgh  
School of Dental Medicine  
Pittsburgh, Pennsylvania

**Denis M. Grant, PhD**

Professor  
Department of Pharmacology and  
Toxicology  
University of Toronto  
Toronto, Ontario, Canada

**Karen S. Gregson, PhD**

Adjunct Professor  
Pharmacology  
Bradley University  
Peoria, Illinois

**David A. Haas, DDS, PhD**

Dean and Professor  
Faculty of Dentistry  
University of Toronto  
Toronto, Ontario, Canada

**David W. Hein, PhD**

Vice Provost for Academic Strategy  
Peter K. Knoefel Endowed Chair  
Professor and Chair  
Department of Pharmacology and  
Toxicology  
University of Louisville  
Louisville, Kentucky

**Elliot V. Hersh, DMD, MS, PhD**

Professor of Oral and Maxillofacial Surgery/  
Pharmacology  
University of Pennsylvania, School of Dental  
Medicine  
Philadelphia, Pennsylvania

**Harrell E. Hurst, MS, PhD**

Professor Emeritus  
Pharmacology and Toxicology  
University of Louisville  
School of Medicine  
Louisville, Kentucky

**William B. Jeffries, PhD**

Senior Associate Dean for Medical  
Education  
Professor of Pharmacology  
University of Vermont  
College of Medicine  
Burlington, Vermont

**Anahid Jewett, PhD, MPH**

Professor and Director of Tumor  
Immunology Laboratory  
Division of Oral Biology and Medicine  
The Jane and Jerry Weintraub Center for  
Reconstructive Biotechnology  
Jonsson Comprehensive Cancer Center  
UCLA School of Dentistry  
Los Angeles, California

**Mo Kwan Kang, MS, PhD**

Professor and Chair  
Section of Endodontics and Division of  
Constitutive & Regenerative Sciences  
UCLA, School of Dentistry  
Los Angeles, California

**Purnima Kumar, BDS, MS, PhD**

Associate Professor  
Division of Periodontology  
College of Dentistry  
The Ohio State University  
Columbus, Ohio

**Karl Kwok, PharmD, RPh**

Clinical Pharmacist-Hematology/Oncology  
University of Washington Medical Center  
Seattle Cancer Care Alliance  
Seattle, Washington

**Binnaz Leblebicioglu, DDS, MS, PhD**

Professor  
Division of Periodontology  
College of Dentistry  
The Ohio State University  
Columbus, Ohio

**Vahn A. Lewis, PharmD, MS, PhD**

Associate Professor  
Diagnostic and Biomedical Science  
UTHealth, School of Dentistry  
Houston, Texas

**Karen M. Lounsbury, PhD**

Professor  
Department of Pharmacology  
University of Vermont  
Burlington, Vermont

**Michael D. Martin, DMD, MSD, MPH, MA, PhD**

Professor  
Department of Oral Medicine  
University of Washington  
Seattle, Washington

**Robert L. Merrill, DDS, MS**

Clinical Professor  
Oral Biology and Medicine  
UCLA  
Los Angeles, California

**Michael Ossipov, PhD**

Research Professor Emeritus  
Department of Pharmacology  
University of Arizona  
College of Medicine  
Tucson, Arizona

**No-Hee Park, DMD, PhD**

Distinguished Professor of Dentistry and  
Dean Emeritus  
UCLA School of Dentistry  
Distinguished Professor of Medicine  
David Geffen School of Medicine at UCLA  
Los Angeles, California

**James C. Phero, D.M.D.**

Professor Emeritus  
Anesthesiology  
University of Cincinnati  
College of Medicine  
Anesthesiology Affiliate Medical Staff  
University of Cincinnati Medical Center  
(UCMC)  
Director Advanced Cardiac Life Support  
(ACLS), AHA Training Center, UCMC  
Department of Anesthesiology  
University of Cincinnati Medical Center  
Cincinnati, Ohio

**Michael T. Piascik, PhD**

Professor and Director of Education  
Department of Pharmacology and  
Nutritional Sciences  
University of Kentucky, College of Medicine  
Lexington, Kentucky

**Frank Porreca, PhD**

Professor  
Department of Pharmacology  
College of Medicine  
University of Arizona  
Tucson, Arizona

**Christine Quinn, DDS, MS**

Clinical Professor  
Dental Anesthesiology  
UCLA School of Dentistry  
Los Angeles, California

**Robert B. Raffa, PhD**

Professor Emeritus and Past Chair  
Department of Pharmaceutical Sciences  
Temple University  
School of Pharmacy  
Philadelphia, Pennsylvania  
Adjunct Professor  
University of Arizona College of Pharmacy  
Tucson, Arizona

**Morton B. Rosenberg, DMD**

Professor Emeritus of Oral and Maxillofacial  
Surgery  
Head, Division of Anesthesia and Pain  
Control  
Tufts University School of Dental Medicine  
Boston, Massachusetts  
Professor of Anesthesiology  
Tufts University School of Medicine  
Boston, Massachusetts

**David H. Shaw, PhD**

Professor and Chairman  
Oral Biology  
University of Nebraska Medical Center  
College of Dentistry  
Lincoln, Nebraska

**Ki-Hyuk Shin, PhD**

Associate Professor  
Oral Biology and Medicine  
School of Dentistry  
UCLA  
Los Angeles, California

**Han-Ching Tseng, PhD, MS**

Quality Manager  
Blood Bank Laboratory Manager  
Grifols Pharmaceuticals  
Los Angeles, California

**Yaping Tu, PhD**

Professor  
Department of Pharmacology  
Creighton University School of Medicine  
Omaha, Nebraska

**Erica C. Vincent, PharmD, BCOP, RPh**

Clinical Pharmacist-Hematology/Oncology  
University of Washington Medical Center  
Seattle Cancer Care Alliance  
Seattle, Washington  
Clinical Instructor  
University of Washington School of  
Pharmacy  
Seattle, Washington

**Dennis W. Wolff, PhD**

Clinical Associate Professor of Pharmacology  
Department of Biomedical Sciences  
University of South Carolina School of  
Medicine  
Greenville, South Carolina



## HOW TO APPROACH PHARMACOLOGY

Although pharmacology can be considered a basic science, the ultimate purpose of pharmacology in the health science setting is to apply basic principles to clinical practice. This book, which is targeted to the dental student and dental practitioner, is designed to meet that need. Pharmacology is important to the dentist not only because of the drugs that he or she prescribes or uses in the dental office but also because of other drugs that the patient takes. Every drug can affect the entire body. Moreover, when more than one drug is given concurrently, there is a potential for drug interactions that could have adverse consequences.

This book is designed to make specific dental applications to each drug class. Included in this information are the benefits and risks associated with those drug classes.

In the study of pharmacology, it is important to learn drugs by their classes on the basis of similarity of mechanism of action rather than individual stand-alone medications. Thus armed with the knowledge of the properties of a class of drugs and examples of drugs within that class, one can streamline the learning process. Organization of drug information can then be arranged around the following subcategories (these will be useful in studying most drugs):

1. Name of drug class and examples
2. Mechanism of action
3. Pharmacokinetics
4. Indications
5. Adverse effects
6. Contraindications
7. Miscellaneous information, including drug interactions
8. Implications for dentistry

Some devices can help in the learning of drug names. The nonproprietary (generic) names for drugs within a given class often have similarities. Being familiar with a list of suffixes of generic drug names can be helpful in identifying an individual drug. Such a list is given next.

## SUFFIXES AS CUES FOR REMEMBERING DRUG CLASSES

Suffix	Drug Class	Example
"azole"	Azole-type antifungal drug or antibacterial-antiparasitic drug	Fluconazole Metronidazole
"caine"	Local anesthetic	Lidocaine
"coxib"	Cyclooxygenase-2 (COX-2) inhibitor	Celecoxib

"dipine"	Dihydropyridine Ca <sup>++</sup> channel blocker	Amlodipine
"ilol" or "alol"	β-Adrenergic receptor blocker that also blocks the α <sub>1</sub> -adrenergic receptor	Carvedilol, labetalol
"mab"	Monoclonal antibody	Infliximab
"olol"	β-Adrenergic receptor blocker	Metoprolol
"onium" or "urium"	Quaternary ammonium compound, usually used as a peripheral compet- itive skeletal muscle relaxer	Pancuronium, atracurium
"osin"	α <sub>1</sub> -Adrenergic receptor blocker	Prazosin
"pam" or "lam"	Benzodiazepine antianxiety agent or sedative hypnotic	Diazepam, triazolam
"pril" or "prilat"	Angiotensin-converting enzyme (ACE) inhibitor	Captopril
"sartan"	Angiotensin II receptor blocker	Losartan
"statin"	HMG CoA reductase inhibitor anti- lipid drug	Lovastatin
"triptan"	Serotonin 5-HT <sub>1B/1D</sub> agonist antiimi- graine drug	Sumatriptan
"vir"	Antiviral drug	Acyclovir

Application of information to clinical cases can increase retention and appreciation of pharmacology. The cases presented in this book help to make that application. The dentist will encounter drugs prescribed by a physician that have adverse effects on the oral cavity. Knowledge of a drug is essential in determining the likelihood of a drug causing adverse oral effects, and what strategies can be used to reduce these effects without compromising the intended therapy. On the other hand, a drug administered by the dentist could impact therapy by the physician. Here again, the dentist will need to have knowledge of that drug to determine whether or not it is advisable to use it in a given patient. These situations require knowledge of how drugs act, including the receptors involved, and what responses are linked to these receptors.

The landscape of pharmacology is ever expanding with the constant development of new drugs, new drug classes, and new information on older drugs. Furthermore, the growth in our knowledge in areas such as pharmacogenetics and pharmacogenomics promises to lead to the practice of tailoring drug therapy to the individual.

All in all, pharmacology is an exciting and dynamic discipline. This book covers the major areas of pharmacology and provides an intellectual framework on which to use drugs in a rational manner.

**Frank J. Dowd**  
**Barton S. Johnson**  
**Angelo J. Mariotti**

# ACKNOWLEDGMENTS

The competing demands of academia in the modern health science setting make the writing of textbooks such as *Pharmacology and Therapeutics for Dentistry* a challenging task. In this effort, we have been aided greatly by our contributing authors, past and present, who have given their time and expertise to ensure that the information provided herein is both accurate and current. We wish to especially acknowledge Dr. John Yagiela and Dr. Enid Neidle, past chief editors of this textbook, for the foundations they set. (Separate tributes to each of them are given earlier.) We specifically acknowledge the contributors to this text who have devoted time and expertise to advancing dental pharmacology. We also must express gratitude to our families, Pat Dowd, Bridgette Mariotti, and Kim Franz, for their forbearance in dealing with our distractions and preoccupations on everything pharmacologic.

We wish to thank several individuals who made special contributions to this work. Ms. Laura Klein, Associate Content Development Specialist with Elsevier, has been our primary contact and associate. She has been most helpful, responsive, kind, and essential to this effort. We deeply appreciate our good times working with her. Ms. Jodie Bernard has been our expert in both her help and responsiveness in her artist role. We also appreciate the work of the following additional professionals at Elsevier: Kathy Falk, the Executive Content Specialist, has given wise direction in this project. Brandi Graham and Jolynn Gower, with their content help, have provided useful assistance in this endeavor. Deepthi Unni has insured that the production of this book has gone smoothly. Jennifer Bertucci has been timely in helping with online submission of documents. Kamatchi Madhavan has provided expert assistance in correcting proofs of the manuscript, and has been our adept project manager. We also recognize Brian Salisbury for his artistic help in the book design.


**Frank J. Dowd**  
**Barton S. Johnson**  
**Angelo J. Mariotti**

# INTRODUCTION

\**Pharmacology* may be defined as the science of drugs and how they affect living systems. The term derives from *pharmakon*, the Greek word for drug or medicine, and *logia*, the Latin suffix traditionally used to designate a body of knowledge and its study. As an organized discipline, pharmacology is of recent origin, but the study of medicinal substances is as old as civilization itself.

## HISTORY


Sir William Osler (1849 to 1919) once said, “The desire to take medicine is perhaps the greatest feature which distinguishes man from animals.” This serves to illustrate the historical relationship between drugs and human beings. The use of natural products to cure disease and alter mentation dates back to the dawn of time. By the writing of the Ebers papyrus (c. 1550 BCE), more than 700 prescriptions for various ailments were known. Many of the ingredients incorporated in these preparations—lizard’s blood, virgin’s hair, fly excreta—are humorous by modern standards, but also included were many compounds recognized today as pharmacologically active. A summary of folk remedies and other medicinals that have withstood scientific scrutiny would list such substances as opium (morphine), belladonna (atropine), squill and foxglove (*digitalis*), cinchona bark (quinine and quinidine), coca leaves (cocaine), and ma huang (ephedrine). The empirical study of plant derivatives and animal products must have been extensive to be so fruitful.



A major hindrance to the effective use of these drugs, however, was the large number of materials usually present in apothecary formulations. For example, the most popular drug of the 15th century, triaca, contained more than 100 separate components. Aureolus Paracelsus (1493 to 1541) was the first to recognize that the indiscriminate mixing of numerous substances did little but dilute whatever effective compounds may have been present initially. The focus of Paracelsus on single agents was refined by Felice Fontana (1720 to 1805), who deduced from his own experiments that each crude drug contains an “active principle” that, when administered, yields a characteristic effect on the body. One of the greatest scientific achievements of the 19th century was the isolation and objective evaluation of such “active principles.”




In 1803, a young German pharmacist, Frederick Sertürner (1780 to 1841), extracted the alkaloid morphine from opium. This singular achievement not only marked the beginning of pharmaceutical chemistry, but it also led to a revolution in experimental biology. The availability of newly purified drugs and the standardization of existing biologic preparations encouraged pioneers like Francois Magendie (1783 to 1855) and Claude Bernard (1813 to 1878) to use pharmacologic agents as probes in the study of physiologic processes. The use of curare by Bernard for the elucidation of the neuromuscular junction is but one example of the successes obtained with this approach. Perhaps because drugs became associated with several biologic sciences and were, of course, considered under the domain of the various medical specialties, the development of pharmacology as a separate discipline was delayed.



\*(Photos in this introduction are as follows: From Wellcome Library, London L0074448, Sir William Osler (1849 to 1919), Canadian physician, aged 63. Copyrighted work available under Creative Commons Attribution only license CC BY 4.0 <http://creativecommons.org/licenses/by/4.0/>. Paracelsus, © Musée du Louvre, © Direction des Musées de France, 1999; Claude Bernard, public domain; John Jacob Abel, public domain; Agonist concentration-response curve; Dioscorides' *Material Medica*, public domain; aspirin tablets, photo © istock.com).


Rudolf Buchheim (1820 to 1879) and Oswald Schmiedeberg (1838 to 1921) were the two individuals most responsible for establishing pharmacology as a science in its own right. Buchheim organized the first laboratory exclusively devoted to pharmacology and became the first professor of his discipline. A student of Buchheim's, Schmiedeberg founded the first scientific journal of pharmacology. More importantly, through his tutelage Schmiedeberg helped spread acceptance of pharmacology throughout the world. One protégé of Schmiedeberg was John J. Abel (1857 to 1938), generally regarded as the father of American pharmacology.

Once an obscure experimental science, pharmacology has expanded its purview to such an extent that the subject has become an important area of study for all health professionals and holds certain interests for the lay public as well. In dentistry, the impact of pharmacology was formally recognized by the American Dental Association in 1934 with publication of the first edition of *Accepted Dental Remedies*.



## SCOPE OF PHARMACOLOGY

Pharmacology is one of the few medical sciences that straddles the division between the basic and the clinical. The scope of pharmacology is so extensive that several subdivisions have come to be recognized. *Pharmacodynamics* is the study of the biologic activity that a drug has on a living system. It includes a study of the mechanisms of action of the drug and the exact processes that are affected by it. The influence of chemical structure on drug action (the structure–activity relationship) is also a concern of this branch of pharmacology. *Pharmacokinetics* deals with the magnitude and time course of drug effect, and it attempts to explain these aspects of drug action through a consideration of dosage and the absorption, distribution, and fate of chemicals in living systems.



*Pharmacotherapeutics* is the proper selection of an agent whose biologic effect on a living organism is most appropriate to treat a particular disease state. It requires a consideration of, among many other things, dose, duration of therapy, and side effects of drug treatment. The practice of *pharmacy* involves the preparation and dispensing of medicines. Although pharmacists today are rarely called on to actually prepare drug products, they are a useful source of drug information for both the clinician and the patient. *Toxicology* is that aspect of pharmacology dealing with poisons, their actions, their detection, and the treatment of conditions produced by them. The importance of toxicology to modern life is continually underscored by new discoveries of chemical hazards in the environment. As the various disciplines of science and medicine have continued to evolve, fruitful areas of inquiry have emerged from the union of fields with overlapping interest. For example, study of the interrelationships between drugs and heredity, aging, and the immune system has led to the respective development of *pharmacogenetics*, *geriatric pharmacology*, and *immunopharmacology*. A final subdivision of pharmacology, *pharmacognosy*, has gained new relevance. Essential at a time when most drugs were derived from plants, it literally means “drug recognition” and deals with the characteristics of plants and how to identify those with pharmacologic activity.

Although most drugs today are synthesized chemically, phytochemistry, especially the synthesis of complex chemical structures by plants, remains of interest. Furthermore, herbal medicine as a discipline of pharmacognosy has gained significant importance since 1994. The use of products in this area has spurred interest in the active components of herbal medicines, their clinical efficacy, and their potential liabilities.

After a description of how the study of drugs is classified, it is appropriate to discuss what is meant by the word *drug*. To the pharmacologist, a drug is any chemical agent that has an effect on the processes associated with life. This definition is obviously broad and ill-suited for many parties who define the term more restrictively to better serve their particular needs. The therapist, for example, considers drugs as those chemicals that are effective in treating disease states. To the lay public, drugs generally connote those substances that cause mental and psychological alterations. Finally, governmental agencies are concerned with the revenue derived from the taxes levied against the sale of certain substances or with public health problems associated with their use. Some of these agents, such as tobacco and alcohol, are legally sequestered—that is, by law they are considered “nondrugs.”



Although pharmacologists have long recognized these agents as potent drugs, they are exempted from the usual governmental restraints and are not subject to normal scrutiny by the U.S. Food and Drug Administration. There are other substances that have gained such special status not by historical accident, as did some of those previously mentioned, but by considerations of public health. Examples of these include chlorine and fluoride added to community water supplies and iodides mixed with table salt. Lawsuits over the question of whether these public measures constitute an illegal form of “mass medication” have been resolved by the courts, at least in part through the categorization of these chemicals as legal nondrugs when they are used in a specific manner for the public good.

Drugs discussed in this book almost exclusively include only those substances with a known therapeutic application. Even so, the potential number of agents for consideration is large: several thousand drugs marketed in a multiplicity of dosage forms and, in some instances, in a bewildering variety of combinations. To limit confusion, emphasis is placed on single, prototypical agents that represent their respective drug classes. By this approach, an understanding of the properties of related agents can be more readily achieved; at the same time, differences that may exist between them can be highlighted. Finally, it is important to recognize that there are certain generalizations that apply to all drugs. These principles of drug action are the subject of the first four chapters in this book. A mastery of the concepts presented in these chapters is necessary for a thorough understanding of pharmacology, for the rational use of therapeutic agents, and for the objective evaluation of new drugs.

## NEW TO THE 7TH EDITION

---

The 7th Edition of *Pharmacology and Therapeutics for Dentistry* is substantially different from previous editions. Some of the chapters from the previous edition (e.g., those not directly related to, or only narrowly focused upon, dental practice) have been removed. Furthermore, the chapters in this edition have focused on content that is pertinent to the dental student. This has resulted in a reduction in chapter and book length. Appendices have been expanded to provide additional reference information. Other changes to the 7th Edition include the following:

- (1) updated pharmacologic information
- (2) revised and expanded illustrations
- (3) dentally related case studies and subsequent discussions
- (4) outlines at the beginning of each chapter
- (5) bolded words and phrases in the text to focus the reader on key concepts and drugs
- (6) color use for the first time

It is our hope that this concise, contemporary, and authoritative edition of *Pharmacology and Therapeutics for Dentistry* will be a great benefit to the pharmacology student and faculty member.

# Pharmacodynamics: Mechanisms of Drug Action\*

Frank J. Dowd and Peter W. Abel

## KEY INFORMATION

- Most drugs bind to, and act through, receptors.
- The vast majority of drug receptors are proteins.
- Five different families of receptors are presented.
- Binding of a drug to a receptor is selective, and the affinity of the binding is measured by its  $K_d$ .
- The effect of the drug after binding to a receptor is called signal transduction. This occurs through a number of steps.
- Drug agonists at a given receptor can be distinguished based upon affinity of binding, potency ( $EC_{50}$ ), and intrinsic activity (maximal effect, also called ceiling effect or  $E_{max}$ ).
- Partial agonists have lower  $E_{max}$  values than full agonists.
- Antagonists are drugs that bind to receptors and block the effects of agonists.
- Antagonists whose blockade of the receptors can be overcome by adding higher concentrations of an agonist are called competitive antagonists.
- Conversely, receptor blockade by a noncompetitive antagonist is not surmountable by adding higher concentrations of the agonist.
- Tolerance to a drug (reduced response to a drug despite continued treatment) can occur by a number of mechanisms, which include desensitization and downregulation of the receptors.
- Receptors are not static structures and can cycle through more than one configuration.

## CASE STUDY

Joe B, your dental patient, takes medication for chronic asthma. He has been given a drug preparation which includes salmeterol, a bronchodilator, and the adrenal corticosteroid fluticasone. His physician has indicated to Joe that he may need a rescue inhaler at times, but the rescue inhaler should not be used unless necessary to reverse an acute asthma attack. In reading about this drug combination, you see there is a "black box" warning that it may increase the risk of death from asthma. Why does it have this warning, and why was Joe warned about the frequency of use of a rescue inhaler?

## DRUGS, RECEPTORS, AND SIGNAL TRANSDUCTION

Pharmacodynamics, which is the heart of pharmacology, is the study of how drugs act to achieve a response. Drugs are chemical substances that are administered to alter or modify existing physiologic or pathologic processes. In conventional doses, most therapeutic agents are generally selective in their action and influence a narrow spectrum of biologic events. How does this happen? Tissue elements to which drugs bind are called **receptors**. They have highly ordered physiologic/biochemical properties that permit only a very few particular compounds to combine with them, while prohibiting all others from doing so. Once bound, the receptor/drug complexes initiate other events to occur at the cellular level.

The existence of receptors that respond to exogenously administered drugs implies that drugs often mimic or inhibit the actions of


endogenous ligands (chemicals that bind) for these receptors. These receptors existed long before drugs were developed. They originally evolved to respond to specific endogenous ligands such as hormones and neurotransmitters. Their great specificity of binding to both endogenous ligands and exogenous drugs suggests that simple molecular modifications of a drug may drastically affect the activity of the drug. This can be beneficial or detrimental to the clinical use of the drug.

### Receptor Classification

For many years after their postulation more than a century ago, receptors remained an enigma to pharmacologists. Little was known about them other than the probability that they were complex macromolecules possessing a ligand-binding site to interact with specific drugs and an effector site to initiate the pharmacologic response. With the development of biochemical methods for the isolation and characterization of proteins, enzymes became available as model systems for the early study of drug-receptor interactions. Enzymes exhibit many of the properties that are ascribed to receptors. They are macromolecules having measurable biologic functions that possess specific reactive sites for selected substrates. The close association between enzymes and receptors was underscored in the early 1940s when it became apparent that some enzymes serve as drug receptors. The list of drugs that alter known enzymatic activities is extensive and includes such examples as angiotensin-converting enzyme inhibitors, anticholinesterases, protease inhibitors, reverse transcriptase inhibitors, statin cholesterol synthesis inhibitors, and various antimetabolites used in cancer chemotherapy, among others.

In addition to enzymes (including coenzymes), other receptors have been identified that are of clinical significance. The most common receptors are those located on and within the various membranes of the cell. Their study has been greatly aided in recent years by

\*The authors wish to recognize Dr. John A. Yagiela for his past contributions to this chapter.



**FIG 1-1** Examples of five major classes of receptors. Arrows denote the receptor ligand-binding sites. **A**, Ion channel-linked receptors. Drugs such as nicotine can activate ligand-gated ion channels, leading to depolarization (or hyperpolarization) of the plasma membrane. **B**, G protein-coupled receptors. Many drugs can activate G protein-linked receptors, causing release of the  $\alpha$  and  $\beta\gamma$  subunits of the G protein. **C**, Transmembrane receptors that have enzymatic cytosolic function. Agents such as insulin and epidermal growth factor activate this type of receptor. **D**, Transmembrane receptors that bind a separate cytosolic enzyme. Cytokines bind to this type of receptor. **E**, Intracellular receptors. Lipophilic substances (dark oval) such as steroids can cross the plasma membrane and activate intracellular receptors.

developments in genomics and proteomics. Many integral membrane proteins function as receptors for endogenous regulatory ligands, such as neurotransmitters, hormones, and other signaling molecules. In addition, membrane transporter proteins and metabolic enzymes, described in Chapter 2 for their influence on drug disposition, are also targets of drug action.

Nucleic acids serve as receptors for a limited number of agents. Certain antibiotics and antineoplastic compounds interfere with replication, transcription, or translation of genetic material by binding, sometimes irreversibly, to the nucleic acids involved. Other drugs, including thyroid hormones, vitamin D analogues, sex steroids, and adrenal corticosteroids, also modify transcription, but here the affected DNA becomes activated or inhibited as a consequence of drug interaction with a separate receptor protein in the cytosol or nucleus of the cell, as will be described subsequently.

Receptors involved in physiologic regulation can be grouped by molecular structure and functional characteristics into several superfamilies. Most of these receptors are membrane bound and have one or more extracellular ligand-binding domains linked by one or more lipophilic membrane-spanning segments to an effector domain often, but not always, located on the cytoplasmic side of the membrane. This arrangement is ideal for the translation of an extracellular signal into an intracellular response. Usually, the endogenous ligand “signal” (upon binding to the receptor) is hydrophilic and incapable of passive diffusion through the cell membrane. The same is true for most drugs that bind to these same receptors. For lipophilic regulatory ligands, such as thyroid hormone and various steroids, a separate superfamily of intracellular receptors exists. Commonly, when these drugs bind, they expose a DNA-binding site on the receptor protein, allowing the receptor to interact with


DNA and alter transcription. These five major classes of receptors are illustrated in [Figure 1-1](#) and described in the following text.

### Ion channel-linked receptors

There are two general classes of ion channels: voltage-gated and ligand-gated (see [Figure 1-1, A](#)). **Voltage-gated ion channels** are activated by alterations in membrane voltage. Voltage-gated  $\text{Na}^+$  channels open when the membrane is depolarized to a threshold potential and contribute to further membrane depolarization by allowing  $\text{Na}^+$  influx into the cell. As described in Chapter 14, local anesthetics such as lidocaine bind to voltage-gated  $\text{Na}^+$  channels, leading to blockade of neuronal depolarization. Specific voltage-gated ion channels also exist for several other ions, particularly  $\text{K}^+$ ,  $\text{Ca}^{2+}$ ,  $\text{H}^+$ , and  $\text{Cl}^-$ .

In contrast, ligand-gated ion channels (see [Figure 1-1, A](#)) are activated in response to the binding of specific ligands or drugs. Another name for ligand-gated ion channels is **ionotropic receptors**. (This term should not be confused with inotropic.) Many neurotransmitters, drugs, and some cytoplasmic ligands activate membrane-bound ligand-gated ion channels. These include several types of glutamate receptors, at least one 5-hydroxytryptamine ( $5\text{-HT}_3$ ) receptor promoting  $\text{Na}^+$ ,  $\text{K}^+$ , or  $\text{Ca}^{2+}$  movements, and certain  $\gamma$ -aminobutyric acid and glycine receptors promoting  $\text{Cl}^-$  influx. Depending on the ionic charge and the direction of flow, ligand-gated ion channels can either depolarize or hyperpolarize the cell membrane.

The nicotinic receptor, the first membrane-bound drug receptor to be fully characterized, is an important example of a ligand-gated ion channel (see generic example in [Figure 1-1, A](#)). An oligomeric structure, the polypeptide constituents of the nicotinic receptor subunits are arranged concentrically to form a channel through which small ions can traverse the plasma membrane when the receptor is activated



**FIG 1-2** Dimerization of two membrane-bound receptor types that activate cytosolic enzymatic activity. Drugs (*blue spheres*) bind to the receptors, leading to dimerization and activation of enzymatic activity on the cytoplasmic side of the receptor (illustrated by conversion of the enzyme from *red* to *green ovals* in **B**). Examples of drugs and other ligands that work through these receptors are shown. **A**, The receptor contains enzyme activity as part of the cytoplasmic end of the receptor. *EGF*, Epidermal growth factor; *PDGF*, platelet-derived growth factor. **B**, The receptor binds and activates a separate enzyme located in the cytoplasm.

by the binding of two acetylcholine (ACh) molecules. As is the case with other ion channels, numerous subtypes of nicotinic receptors exist expressing differing affinities for specific ligands.

### G protein-coupled receptors

G protein-coupled receptors, sometimes referred to as metabotropic receptors, constitute the largest superfamily of integral membrane proteins, and collectively serve as targets for approximately half of all non-antimicrobial prescription drugs (see [Figure 1-1, B](#)). The basic structure of these receptors includes a common seven-membered transmembrane domain. Generally, metabotropic receptors greatly amplify extracellular biologic signals because they activate G proteins, which activate ion channels or, more commonly, other enzymes (e.g., adenylyl cyclase), leading to the introduction or formation of a host of internal second messengers for each extracellular signal molecule detected.

G proteins are heterotrimers consisting of  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits. After receptor activation, guanosine diphosphate (GDP, attached to the  $\alpha$  subunit) is replaced by guanosine triphosphate (GTP), and the heterotrimer splits into the  $\alpha$  monomer and  $\beta\gamma$  dimer. Many, but not all, of the observed cellular actions are caused by the  $\alpha$  subunit. As an example,  $G_{\alpha s}$ , the specific  $\alpha$  subunit for the G protein associated with  $\beta$ -adrenergic receptors, activates adenylyl cyclase, which catalyzes the synthesis of cyclic adenosine 3',5'-monophosphate (cAMP). cAMP activates protein kinase A, which catalyzes the phosphorylation of serine and threonine residues of certain intracellular proteins, leading to a complex alteration in cellular function.

The G protein system is very complex. One receptor subtype may activate different G proteins, several receptor subtypes may activate the same G protein, and the ultimate target proteins can exist in tissue-specific isoforms with differing susceptibilities to secondary effector systems. The different G protein pathways can also interact with one another. The complexity of G protein signal transduction provides a sophisticated regulatory system by which cellular responses can vary, depending on the combination of receptors activated and the cell-specific expression of distinct regulatory and target proteins. Several specific membrane-bound G proteins are discussed beginning in Chapter 5 and continuing thereafter with regard to several clinical drugs discussed in the text.

### Transmembrane receptors that have enzymatic cytosolic function

Enzyme-linked receptors have only one transmembrane domain per protein subunit, with an enzymatic catalytic site on the cytoplasmic side of the receptor (see [Figure 1-1, C](#)). For many of these receptors, dimerization activates the receptor to provide the conformational change required for expression of enzymatic activity. The most important cytoplasmic sites have one of the following functions: (1) tyrosine kinase activity, (2) tyrosine phosphatase activity, (3) serine or threonine kinase activity, or (4) guanylyl cyclase activity. For types 1 and 3, autophosphorylation of the receptor also occurs at tyrosine sites and at serine/threonine sites, respectively. [Figure 1-2](#) shows how some of these receptors dimerize after a drug agonist binds.



**TABLE 1-1 Receptor Types, Examples, and Approximate Time Until a Noticeable Response Occurs After Receptor Stimulation**

Receptor Type	Some Receptor Examples	Time
Ion channel	Nicotinic cholinergic GABA <sub>A</sub> Glycine	Milliseconds
G protein–linked	Muscarinic cholinergic Adrenergic ( $\alpha$ and $\beta$ ) Opioid Histamine	Seconds
Transmembrane with cytosolic enzyme domain	Epidermal growth factor Platelet-derived growth factor Insulin	Minutes to hours
Transmembrane that binds to a separate cytosolic enzyme	Cytokines (e.g., interleukins, interferons, tumor necrosis factors)	Minutes to hours
Intracellular (nuclear target)	Thyroid Estrogen Vitamin D	Hours to days

Many forms of cancer seem to involve mutant variants of enzyme-linked receptors in which the catalytic site or associated nonreceptor protein kinase is continuously activated. Approximately half of all oncogenes discovered to date encode for continuously activated protein kinases.

### Transmembrane receptors that bind to a separate cytosolic enzyme

Another type of transmembrane receptor is one that has a noncatalytic domain that activates a separate cytosolic tyrosine kinase, called Janus kinase (JAK), that phosphorylates separate cytosolic proteins. This receptor dimerizes after binding to the kinase (see Figure 1-2) and is the type of receptor to which cytokines bind (see Figure 1-1, *D*).

### Intracellular receptors

Lipophilic substances capable of crossing the plasma membrane may activate intracellular receptors (see Figure 1-1, *E*). Sex steroids, mineralocorticoids, glucocorticoids, thyroid hormones, and vitamin D derivatives all activate specific nuclear receptors that influence DNA transcription. When a drug (or hormone) binds to the receptor, it folds into the active configuration and dimerizes with a partner receptor. The conformational change results in a dramatic increase in binding to specific DNA sequences. Binding of thyroid hormone to its receptor produces more than a tenfold increase in receptor affinity for binding to DNA. DNA binding of the activated receptor often initiates transcription, leading to increased production of specific proteins. Because this type of signal transduction requires protein synthesis, drugs that activate intracellular receptors typically have a delay of several hours before the onset of their pharmacologic effect. (This is the reason glucocorticoids cannot be used as primary drugs for the management of anaphylaxis.) In some systems, the binding of the drug-receptor complex inhibits transcription. Regardless of the specific mechanism involved, however, the intensity and duration of drug effect are temporally independent of its plasma concentration.

Table 1-1 indicates the relative speed of response for the various types of receptors.

In addition to these intracellular receptors, other enzymes and proteins involved in cell function and gene expression are receiving increasing scrutiny as potential targets for drug therapy. Nitric oxide, which stimulates guanylyl cyclase directly to form cyclic guanosine

3',5'-monophosphate (cGMP), and sildenafil, which inhibits the breakdown of cGMP by cGMP-specific phosphodiesterase-5, are two examples of currently available agents acting intracellularly on regulatory enzymes. Finally, structural proteins such as tubulin, which are assembled to form microtubules, are targets for several drugs used in the treatment of cancer, gout, and fungal infections.

### Drug-Binding Forces

Implicit in the interaction of a drug with its receptor is the chemical binding of that drug to one or more specific sites on the receptor molecule. Multiple bond formation often accompanies the interaction between a drug and receptor. Four basic types of binding are pictured in Figure 1-3. Drug-binding forces vary in strength. Hydrophobic binding is often very weak, whereas covalent binding can be quite strong (e.g., the acetylation of a receptor shown in Figure 1-3).

Most drugs reversibly bind to their receptors. As described in Chapter 2, the duration of action of drugs is related to how long an effective drug concentration remains in the vicinity of the drug receptors. This time may vary from a few minutes to many days, but usually it is on the order of minutes to hours. If a drug irreversibly binds to a receptor, new receptor synthesis is usually required to reverse the effect of the drug.

### Structure–Activity Relationships


Examination of structure–activity relationships (SARs) is a time-honored method of studying drug–receptor interactions. In SAR investigations, specific features of the structure of a drug molecule are identified and then altered systematically to determine their influence on pharmacologic activity. SAR studies of closely related agents (congeners) led to an understanding of the chemical prerequisites for pharmacologic activity and, on a practical level, made possible the molecular modification of drugs to provide enhanced or even novel therapeutic effects, while reducing the incidence and severity of toxic reactions. In addition, SAR studies serve to illustrate how the combined action of the various binding forces described earlier are necessary for maximal drug activity. This yields certain clues concerning the physicochemical properties of the receptor sites involved that are of value to investigators seeking to unravel the exact structure of these sites. X-ray crystallography techniques have shed light on not only the structure of receptors but the different functional conformations of the receptor and their relation to drug binding. All of the drug-binding forces shown in Figure 1-3, as well as drug size and conformation(s) (see following), are important contributors to drug structure–activity relationships.

### Drug Size, Shape, and Isomerism

Most clinically useful drugs are organic compounds that have molecular weights less than 1000 and greater than 100. Exceptions include drugs such as the inorganic compound lithium carbonate and some of the newer biologic proteins, which can have molecular weights in the range of 150,000. Selectivity of a drug for a receptor is dependent on the three-dimensional structure of the drug. Thus, conversion of a *cis*- to a *trans*- conformation of a drug can have dramatic effects on affinity. Optical isomers of drugs often have very different affinities for the same receptor. Norepinephrine, for instance, is supplied in a dextrorotary (*d*) and a levorotary (*l*) form. (The two are often combined.) The *l* conformation has a tenfold higher affinity for adrenergic receptors than the *d* conformation, reflecting the importance of the three-dimensional structure as seen in mirror images.

### Events Following Drug Binding: Signal Transduction

The combination of a drug with its receptor represents the first event in a series of reactions that culminate in a pharmacologic effect. An



**FIG 1-3** Four chemical bonds associated with drug–receptor interactions. Dotted areas indicate the region of the bonds.

important second step in this chain is the receptor response to drug binding. Drugs generally are not highly reactive compounds in the chemical sense; they exert their influences indirectly by altering, through their receptor attachment, the activity of an important regulator of a biologic process. The mechanism of action of a drug refers to this perturbation of normal function.

Activation of a receptor by a drug leads to a cascade of events that eventually results in an observable pharmacologic effect. These events constitute the **signal transduction pathway**, which is also called **stimulus–response coupling**. Individual receptor types have different signal transduction pathways (Figure 1-4).


### Ion channel receptors

Ion channel receptors react to drugs by either increasing or decreasing their conductance. Channels are usually selective for a single ion. The increase or decrease in conductance of an ion leads to a cell event such as depolarization of the cell, hyperpolarization of the cell, or calcium signaling (see Figure 1-4, A). Nicotinic receptors and chloride channel receptors are examples of this class of receptors.


### G protein–linked receptors

G protein–linked receptors encompass a variety of signaling pathways. G proteins are classified based on the nature of their  $\alpha$  subunit. Three different types of G protein–coupled receptors are shown in Figure

1-4, B and C. The G protein complex is inactive when GDP is bound to the  $\alpha$  subunit, which happens when the receptor is not stimulated by an agonist. Receptor stimulation leads to dissociation of GDP from the  $\alpha$  subunit and the replacement binding of GTP (Figure 1-4, B and C). When this happens, the  $\alpha$  subunit dissociates from the  $\beta\gamma$  subunit complex and then affects the activity of a nearby enzyme. In the case of  $G\alpha_s$ , the effect is to stimulate the enzyme adenylyl cyclase. Alpha subunits possess GTPase activity, which allows the G protein subunits to reassociate and return to an inactive state when the receptor is no longer stimulated. The activated function of adenylyl cyclase is to convert ATP to cyclic AMP (cAMP), which leads to activation of cAMP-dependent protein kinases (PKA) and resulting cell changes. The opposite effect, (i.e., inhibition of adenylyl cyclase) occurs when a different type of G protein–linked receptor releases  $\alpha_i$ , bound to GTP. A third type of G protein–linked receptor involves the release of  $\alpha_q$ . Alpha<sub>q</sub> activates phospholipase C (PLC), which converts phosphatidylinositol-bisphosphate (PIP<sub>2</sub>) to inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG). Both are important for calcium signaling. IP<sub>3</sub> causes the release of calcium from intracellular stores, and DAG stimulates protein kinase C (PKC). In several cases the  $\beta\gamma$  subunit also participates in signal transduction, for instance, by affecting ion channels. Drugs that act through  $\alpha_s$  are said to act through G<sub>s</sub> (the G protein containing  $\alpha_s$ ) and include drugs that stimulate the  $\beta$ -adrenergic receptor. Likewise, drugs that act through G<sub>i</sub> include drugs



**FIG 1-4** Signal transduction pathways. **A**, Ion channel receptors react to drugs by either increasing or decreasing their conductances. Although the conductances for  $\text{Na}^+$  and  $\text{Ca}^{2+}$  are shown in the same channel, typically channels are more selective for one type of ion. Channels vary as to their selectivity for cations or anions. Drug-binding sites are indicated by *arrows* on either side of the channel. **B and C**, Three different types of G protein–coupled receptors are shown: receptors coupled to  $G_s$ ,  $G_i$ , and  $G_q$ . The pathways are explained in the text. *Arrows* indicate the sites of drug binding on the receptor. *GDP*, Guanosine diphosphate; *GTP*, guanosine triphosphate; *PLC*, phospholipase C; *PIP<sub>2</sub>*, phosphatidylinositol-bisphosphate; *IP<sub>3</sub>*, inositol 1,4,5-trisphosphate; *DAG*, diacylglycerol; *PKA*, cyclic AMP-dependent protein kinase; *PKC*, protein kinase C. **D**, Transmembrane receptors that have enzymatic cytosolic activity. In the example given, tyrosine kinase causes the phosphorylation of a separate substrate (as well as autophosphorylation, not pictured). *TK*, Tyrosine kinase.



**FIG 1-4, cont'd E.** Transmembrane receptors resembling those that have enzymatic activity (e.g., tyrosine kinase) but are lacking enzymatic activity on the receptor. A separate cytosolic tyrosine kinase, JAK, is shown, which causes phosphorylation of STATs. Activated STATs dimerize and migrate to the nucleus to induce transcription. TTCN<sub>2-4</sub>GAA is the DNA consensus binding element for STAT. JAK, Janus kinase; STAT, signal transducer and activator of transcription. **F.** Nuclear receptors. Drugs (dark ovals) bind to receptors in the cytoplasm; the complex translocates to the nucleus and causes changes in transcription.

that stimulate the  $\alpha_2$ -adrenergic receptor. Drugs that act through  $G_q$  include those that stimulate the muscarinic cholinergic receptor.

Epinephrine provides a useful illustration of the complex downstream consequences of drug binding. Incorporated into local anesthetic solutions to prolong the duration of pain relief, epinephrine mimics the action of the neurotransmitter norepinephrine. As a result of epinephrine attachment to  $\alpha_1$ -adrenergic receptors on vascular smooth muscle cells, the G protein known as  $G_q$  is activated, phospholipase  $C_\beta$  activity is stimulated, and the membrane lipid phosphatidylinositol-4,5-bisphosphate is broken down to yield the second messengers diacylglycerol and inositol-1,4,5-trisphosphate ( $IP_3$ ). Diacylglycerol initiates a cascade of metabolic events that support muscle contraction.  $IP_3$  causes the release of  $Ca^{2+}$  from intracellular

storage sites, which induces the activation of actomyosin and initiates vasoconstriction.

### Transmembrane receptors that have enzymatic cytosolic activity

Insulin and several growth factors act through this type of receptor. Enzymatic activity on the cytosolic aspect of the receptor catalyzes changes that lead to the characteristic cell changes. In the example given in Figure 1-4, D, after insulin binds extracellularly, intracellular tyrosine kinase causes the phosphorylation of a separate substrate (as well as autophosphorylation, not pictured). Activation of several subsequent pathways such as the MAP kinase pathway follows, leading to further changes such as transcription in the nucleus.

### Transmembrane receptors that bind to a separate cytosolic enzyme

Various cytokines act through these receptors. These receptors require a separate cytosolic tyrosine kinase to complete their function as receptors (see Figure 1-4, E). Typically, this enzyme is a JAK, which phosphorylates a group of proteins called signal transducers and activators of transcription (STATs). Activated STATs dimerize and migrate to the nucleus to induce transcription of selective genes. As can be surmised, many other steps are involved in the complex array of secondary signaling pathways.

### Intracellular (nuclear) receptors


Steroid hormones, vitamin D, and thyroid hormone act through this type of pathway. Drugs that bind to these receptors diffuse into the cell and bind to intracellular receptors (see Figure 1-4, E). Dimerization with a co-receptor protein usually occurs after drug binding, followed by movement of the entire complex into the nucleus and induction of transcription of selective genes by binding to specific response elements (promoters/enhancers) on the DNA. Other steps are involved in the signaling pathways, and several other proteins, including co-activators and co-inhibitors, are involved in shaping the final transcription process.

## CONCENTRATION–RESPONSE RELATIONSHIPS

A fundamental aspect of drug action is the relationship between the dose administered and the effect obtained. As one would expect, the magnitude of a chemical's effect on a system is positively correlated with the quantity or concentration of that chemical. For example, to increase the saltiness of a food, more salt must be added. Within certain limits, the addition of salt yields a graded and (nearly) linear response. However, with repeated additions of salt, the increase in saltiness becomes less and less until finally, further additions do not increase the sensation of greater saltiness. The dose–effect relationship of a drug is similar and is not a linear function throughout the entire dose range. Below a minimum threshold, there will be no observable effect. Above a certain ceiling, even a large dose would exert no additional effect because the maximal effect has already been reached.

### Occupation Concept

Clark attempted in the 1920s to quantify drug effects through application of the law of mass action. Out of his efforts, and the contributions of others, emerged the occupation concept of drug action. The occupation concept holds that the magnitude of a pharmacologic response elicited by a drug that reversibly combines with its receptor is directly proportional to the number (or fraction) of receptors occupied by the drug. The relationship can be written as follows:




where  $D$  is the drug,  $R$  is the receptor, and  $k_1$  and  $k_2$  are rate constants. At equilibrium  $k_2/k_1 = K_d$  (the dissociation constant). The  $K_d$  is a measure of the **affinity** of the drug for the receptor: the smaller the  $K_d$ , the greater the affinity.

After binding ( $DR$ ) has occurred, an effect ( $E$ ) follows, usually after several intervening signal transduction steps following binding, as described earlier. These intervening steps are represented by a single arrow in the preceding equation. A derivative of the Michaelis-Menton equation can be used to quantify drug effects as follows:

$$E = \frac{E_{\max} \times [D]}{K_d + [D]}$$

(where  $E_{\max}$  = maximal effect or ceiling effect)




**FIG 1-5** Theoretical concentration–response curve (log scale) for a smooth muscle stimulant. As shown, the linear portion of the sigmoid curve, extending from approximately 25% to 75% of the maximal effect, is encompassed by a tenfold concentration range. A range of 10,000 times is required, however, to depict the curve in its entirety (from 1% to 99% of the maximal effect). The concentration yielding 50% of the maximal response ( $EC_{50}$ ) is also shown.  $E_{\max}$ , ceiling effect = intrinsic activity.

Based upon this equation, the effect of the drug is predictably and quantitatively dependent on the drug concentration. Moreover, a geometric relationship (rectangular hyperbola) exists when graphing  $E$  versus  $[D]$ . The drug concentration is usually expressed in  $\log_{10}$  units. This mathematic relationship between the concentration of a drug and its response may be shown visually by an experiment in which an isolated muscle is exposed to increasing concentrations of a drug while the force of contraction is measured (Figure 1-5).

When a drug is introduced into a tissue, it binds to its receptor in accordance with the  $K_d$  for that drug at that receptor. Each muscle cell may require a minimal number of receptors to be occupied before it contracts. The lowest concentration to elicit a measurable response is termed the **threshold concentration**. As higher concentrations are used, the number of receptors occupied increases, as does the intensity of response. An increase in the fraction of receptors occupied necessarily reduces the number available for subsequent binding so that at high concentrations each increment of drug produces progressively smaller additions to the magnitude of contraction. At very high concentrations, the receptor population becomes saturated, and further drug administration no longer influences contraction. A maximal muscle response for the drug, termed the **ceiling effect**, or  $E_{\max}$ , is achieved.

The useful concentration range for a drug falls between the threshold and the ceiling ( $E_{\max}$ ). By expressing data as the logarithm of the concentration versus the degree of response, this important and normally hyperbolic segment of the concentration–effect relationship becomes a sigmoid curve with the linear central portion typically extending over a tenfold concentration range. The concentration of a drug that produces a half-maximal response ( $EC_{50}$ ) is often used to compare potencies of various drugs. The  $EC_{50}$  depends in part on the  $K_d$ , but it is not necessarily equal to the  $K_d$ . When data from several experiments are expressed on a single graph with the log concentration of the drug, this value can be accurately determined for each drug from the linear portion of the respective curve. Notice that the log concentration of the drug is plotted against a graded response in the tissue. A graded response is one in which the magnitude of the response increases incrementally as the drug concentration is increased. The curves generated are therefore called **graded log concentration**



**FIG 1-6** Concentration-effect curves for two drugs differing in receptor affinity by a factor of 100. *Left*, A log scale. Note the identical shapes of the two concentration–effect relationships. *Right*, An arithmetic scale. The lack of correspondence between the two curves hinders the drug comparison of the two drugs. Note that the units on the ordinate are percentages of  $E_{\max}$ .

**response curves.** If the concentration data were not logarithmically transformed, graphical analysis would become more complex. **Figure 1-6** illustrates the difficulties encountered if two drugs differing only in receptor affinity are examined on an arithmetic scale. The curve for drug A is so compressed that the concentration yielding the  $EC_{50}$  cannot be easily ascertained; for drug B, it cannot even be represented on the same page.

### Agonists


Drugs, or other ligands, that bind to a receptor and elicit a response from a tissue are known as **agonists**. Agonists that produce ceiling effects—effects that are not exceeded by other drugs—are called **full agonists**, and drugs whose maximal effects are less than those of full agonists are referred to as **partial agonists**. The distinction between full and partial agonists is unrelated to differences in receptor affinity; rather, it is due to differences in their abilities to activate signal transduction changes after binding. The difference between these two classes of agonists lies in their unequal **intrinsic activities**.  $E_{\max}$  is the measure of the **intrinsic activity** of a drug. Intrinsic activity is the ability of a drug to activate a receptor after the drug–receptor complex has formed. Incorporating intrinsic activity into the concentration–effect equation yields:

$$E = \text{intrinsic activity} \cdot \frac{E_{\max} [D]}{K_d + [D]}$$

Thus, drugs with a low intrinsic activity are **partial agonists**. The log concentration–response curve of a partial agonist has a lower maximum and a reduced slope compared to that of a full agonist (**Figure 1-7**).

Two drugs (A and B) with the same intrinsic activity are shown in **Figure 1-7**, in which two agonists of muscle contraction are compared. The muscle was removed from the animal, placed in a bath containing an oxygenated physiologic salt solution, and attached to a strain gauge to measure contractions. In such experiments, conditions can be manipulated to ensure that each drug tested has equal access to the receptor in question. This condition greatly simplifies the interpretation of experimental results and cannot readily be duplicated in whole-animal investigations.

In addition to intrinsic activity, one other term is important in **Figure 1-7**: **potency**. Potency is the concentration (or dose) of the drug needed to achieve a given level or amount of response. The potency of drugs is reflected in their position on a concentration–response curve; the further



**FIG 1-7** Theoretical concentration–response curves for three agonists acting at the same receptor. Drugs A and B have the same intrinsic activity ( $E_{\max}$ ), but B has less potency than A. Drug C has a lower intrinsic activity than either A or B, but it has the same potency as drug A (as measured by the  $EC_{50}$ ).

to the left the drug response curve lies, the more potent the drug. The potency of a drug is usually expressed as the concentration of the drug required to achieve a half-maximal stimulation of the response ( $EC_{50}$ ). The lower the  $EC_{50}$ , the greater the potency. In **Figure 1-7**, drug C has a lower intrinsic activity than either A or B; however, its potency is the same as that of drug A (because the  $EC_{50}$  values for both A and C are equal). The potency of drug C is greater than that of drug B. Because drug C has a lower intrinsic activity than either drug A or B, drug C is termed a **partial agonist**.


The terms affinity, intrinsic activity, and potency are conceptualized in **Figure 1-8**. This figure shows the equation linking a drug to an effect, and how affinity, intrinsic activity, and potency are related. Potency is related to affinity but is not the same as affinity. Affinity relates only to binding to a receptor; potency requires binding and achieving a response. Clinically however, the potency of a drug is also influenced by additional factors such as the drug’s ability to reach the receptor (determined by the rate of absorption and the patterns of distribution and elimination). Since the concentration of a drug at the receptor is not known, clinical potencies are based on dose and are usually measured as the  $ED_{50}$  (effective dose to achieve 50% of the maximal response).

Notice that the term affinity relates only to the binding of the drug to its receptor, whereas intrinsic activity and potency encompass both binding and subsequent signal transduction events leading to a response. Full agonists are those that have an  $E_{\max}$  that is the highest for any agonist at that receptor. Partial agonists have lower  $E_{\max}$  values and therefore have lower intrinsic activity.

Figures 1-5, 1-6, and 1-7 show tissue responses to drugs and therefore are the types of graphs from which intrinsic activity and potency can be derived. On the other hand, the  $K_d$  of a drug is derived solely from binding data such as that obtained from a radioligand binding experiment, in which experiments are conducted using a radiolabeled drug in the presence of a receptor. Analysis of responses to drugs is often complicated by the fact that more than one drug molecule may bind simultaneously to a given receptor, one binding event may influence another, and the pharmacologic response may not be proportional to the number of receptors occupied by an agonist.

### Indirect agonists

The discussion about agonists (full or partial) has to this point been about drugs that act directly on receptors: **direct agonists**. **Indirect**




**FIG 1-8** Depiction of drug characteristics. Affinity relates solely to drug binding, whereas intrinsic activity and potency encompass both binding and the events that follow leading to an effect.

**agonists** are those that increase the level of direct agonists often by reducing the rate of metabolism of the direct agonist. A good example is the use of cholinesterase inhibitors to increase endogenous levels of acetylcholine, thereby increasing the effect of acetylcholine at its receptors.

### Antagonists

Drugs that inhibit the effects of agonists are called **antagonists**. Pure antagonists have an intrinsic activity of zero because they bind to receptors but do not activate signal transduction pathways. Antagonists that bind reversibly to a receptor at the same site as the agonist are **competitive antagonists**. By making receptors less available for agonist binding, a competitive antagonist depresses the response to a given dose or concentration of agonist. The result is a parallel shift to the right of the agonist concentration-response curve (see Figure 1-9). An important aspect of this type of inhibition is that it is completely surmountable by a sufficiently high concentration of agonist. The presence of a competitive antagonist produces an apparent reduction in the affinity of an agonist for its receptor. The affinity of a competitive antagonist is measured as the  $K_i$ , which is equivalent to the  $K_d$  for an agonist. Competitive antagonists are common in pharmacology, and numerous examples are cited in succeeding chapters: antihistamines versus histamine, naloxone versus morphine, propranolol versus epinephrine, to name a few. By virtue of its small intrinsic activity, a partial agonist can also serve as a competitive antagonist of a full agonist. The aggregate receptor-stimulated event from the combination depends on the relative drug concentrations, receptor affinities, and intrinsic activities of the two agents.

Another type of antagonism commonly encountered is **noncompetitive**. The noncompetitive blockade is insurmountable in that the ceiling effect of an agonist can never be reattained, regardless of the concentration of the agonist that is administered. One way a noncompetitive antagonist can act is to decrease the effective number of receptors by irreversibly binding to the receptor site. The result of noncompetitive inhibition is a downward displacement of the agonist log concentration-response curve. Figure 1-9 reviews the dissimilarities between the two classic types of drug blockade. Competitive antagonists increase the  $EC_{50}$  of the agonist but do not affect the intrinsic activity of the agonist. Noncompetitive antagonists decrease the apparent intrinsic activity of the agonist with little effect on its  $EC_{50}$ .



**FIG 1-9** Effect of drug antagonism on a concentration response profile of an agonist. The left panel shows the effect of a competitive antagonist. Note that the  $EC_{50}$  values for the agonist increase with increasing concentrations of the antagonist. The right panel shows the effect of a noncompetitive antagonist. Note that the  $EC_{50}$  values for the agonist do not change with the antagonist.

### Allosteric effects

Drugs that bind to receptors and affect the function of the receptor but do so at a site that is different from the usual ligand are said to act at an **allosteric** site. Drugs that act allosterically can either increase or decrease the receptor response. Allosteric inhibitors are another mechanism of noncompetitive inhibition.

### Spare receptors

It is quite common for full agonists to achieve their maximal effect without occupying all of the relevant receptors of a cell. This is because extra receptors are present. This phenomenon is called the **spare receptor** concept or **receptor reserve**. It is demonstrated experimentally by achieving the  $E_{max}$  at a concentration of a drug that does not bind all of the receptors. It is also demonstrated by the effect of a noncompetitive antagonist. Instead of the predictable decrease in  $E_{max}$  when the noncompetitive antagonist is added, there is a shift to the right of the agonist response curve until all spare receptors have been bound by the noncompetitive antagonist. At that point, adding more antagonist generates the predictable decrease in  $E_{max}$  of the agonist.

### Receptor Diversity

In addition to the fact that pharmacologic responses are often not linearly related to receptor occupancy, situations exist in which the receptors for a drug are not identical to one another. A repeating theme in the elucidation of the autonomic nervous system has been the division of receptor classes into an increasing array of types and subtypes with differing drug sensitivities. Part of the explanation for the unusual pharmacology of tamoxifen was made clear by the discovery that there were two subtypes of estrogen receptors in various tissues that responded differently to this agent. Individuals may even harbor differences in receptor structure based on single point mutations. An important example is the  $\beta_2$ -adrenergic receptor, for which numerous single nucleotide polymorphisms have been identified that may alter drug responsiveness in diseases such as asthma.

### Pharmacodynamic Tolerance


The preceding discussion of concentration–response relationships is further complicated by the fact that the drug effect on the receptor can change with the passage of time. **Pharmacodynamic tolerance** is a general term for situations in which drug effects dissipate with time despite the continued presence of the agonist at a fixed concentration. At the receptor level, various processes in addition to the primary drug effect are often invoked that subsequently limit pharmacologic responses. In the case of the  $\beta$ -adrenergic receptor, phosphorylation of specific amino acid constituents leads to a loss of drug action or a large decrease in drug response, a process termed **desensitization** (Figure 1-10).

The loss of drug action can be measured by a lack of increase in cyclic AMP or some other reduction in the signaling pathway. In this example, agonist-induced phosphorylation by a G protein–coupled receptor kinase (GRK) of the  $\beta$ -adrenergic receptor induces binding of a protein,  $\beta$ -arrestin, which prevents the receptor from interacting with  $G_s$ . Removal of the agonist for a short time (e.g., several minutes) allows dissociation of  $\beta$ -arrestin and removal of phosphate from the receptor by phosphatase, resulting in restoration of the receptor's normal responsiveness to the agonist. A separate mechanism, internalization, can occur in which endocytotic membrane trafficking of the receptors takes place. This is also promoted by  $\beta$ -arrestin and takes place after longer exposure to an agonist. After internalization, receptors can either be shuttled back to the plasma membrane or destroyed by lysosomal enzymes. Internalization accounts for **downregulation** of the receptors.

Pharmacodynamic tolerance may also occur independently of any change in the drug receptor or stimulus–response system. As an illustration of this point, consider a drug that increases blood pressure by causing vasoconstriction in selected vascular beds. In response to the increase in blood pressure, various cardiovascular reflexes are evoked that reduce blood pressure, including activation of the parasympathetic nervous system, which causes bradycardia. The buildup of lactate and other metabolites in the affected tissues also limits vasoconstriction. Eventually, additional changes, such as decreased salt and water retention, may also reduce drug-mediated increases in blood pressure responses even further. These and other mechanisms of drug tolerance are described more fully in Chapter 3.

### Multistate Model of Drug Action

Receptors may exist in more than one conformation. According to the multistate model of drug action, these forms of receptors are in equilibrium, and drugs act by altering their relative distributions. Figure 1-11 illustrates a simple two-state version in which the receptor can exist in an active or inactive conformation.




**FIG 1-10** Rapid desensitization and long-term downregulation of the  $\beta$ -adrenergic receptor. Both events lead to a lack of a response when the receptor is stimulated by an agonist. *GDP*, Guanosine diphosphate; *GTP*, guanosine triphosphate;  $\textcircled{P}$ , phosphorylation on carboxyl terminal hydroxyl groups; *GRK*, G protein–coupled receptor kinase;  *$\beta$ ARR*,  $\beta$ -arrestin which prevents the receptor from interacting with  $G_s$ . Refer to text above for further details.



In this model, full and partial agonists increase the proportion of receptors that exist in the active state. Receptors, in the absence of a ligand, tend to be in the inactive state. The degree to which they exist in the active state without an agonist corresponds to a level of activity which is called **constitutive activity**. Drug agonists bind to the receptor, converting the receptor to the active state. This is reflected in the difference in sizes of the reaction arrows (see Figure 1-11). Partial agonist binding produces an insufficient active form of the receptor to yield a maximal response (Figure 1-12). Competitive antagonists associate with receptors regardless of—and without influencing—their conformational state. Therefore Figure 1-12 shows no change in the active form of the receptor as a result of binding of a competitive antagonist. Noncompetitive antagonists limit the ability of agonist binding to elevate the number of receptors in the active state by reducing the total number of available receptors.

The major attractions of the multistate model are that it gives a solution for differences in the magnitude of the response between structurally related drugs, and that it affords a simple mechanism for the pharmacologic response elicited by drug binding. It also provides an explanation for drugs known as **inverse agonists**. An inverse agonist causes an effect opposite to that of the agonist, in contrast to a competitive antagonist, which simply blocks the agonist (or the inverse agonist) but has no inherent effect by itself (see Figure 1-12). In a tonically active pathway, in which the receptor has constitutive activity (without drug), a drug that preferentially binds to the inactive configuration or induces its formation would behave as an inverse agonist. In other words, inverse agonists inhibit endogenous activity of a receptor. For example, flumazenil, a competitive antagonist of the benzodiazepine receptor, reverses the effects of both agonists and inverse agonists. Additional examples of inverse agonism have been shown for various G protein-coupled receptors overexpressed in cells experimentally or after neoplastic transformation. Inhibition of constitutionally active oncogenes by inverse agonists may provide a new strategy for cancer chemotherapy.

A final advantage of the multistate model is that it can accommodate desensitization and time-dependent actions of drugs such as nicotine. Nicotine exhibits a complex pharmacologic profile. Initially, this natural alkaloid acts like an agonist: it stimulates ACh receptors at autonomic ganglia and in skeletal muscle. The stimulation is temporary, however, and in minutes the action of nicotine transforms from that of excitation to one of antagonism. This metamorphosis can be adequately explained if one assumes that a third, or “desensitized,” configuration of the receptor exists to which active receptors are slowly converted and from which they even more slowly recover. Nicotine,



**FIG 1-11** Two-state model of drug-receptor interaction. The receptor can exist in an active ( $R_a$ ) or inactive ( $R_i$ ) state. Unless the receptor mediates a tonically active process, without any drug, only the inactive state is present. Drugs ( $D$ ) may bind to  $R_a$ ,  $R_i$ , or both. Agonist binding favors the formation of  $DR_i$  and  $DR_a$ . The ratio of  $DR_a/DR_i$  influences the degree of response to the drug. The level of  $R_a$  corresponds to the degree of constitutive activity of the receptor.


by increasing the proportion of active receptors, causes an initial stimulation and a subsequent prolonged loss of activity as receptors are progressively trapped in the desensitized state. Ion channel desensitization is a different mechanism of desensitization from that depicted in Figure 1-10.

## RECEPTOR-INDEPENDENT DRUG ACTIONS

No description of drug action would be complete without a consideration of agents that exert pharmacologic effects through receptor-independent mechanisms. Aside from the fact that these drugs act without the benefit of receptor intermediaries, there are no common traits serving to link this miscellaneous array of compounds. It has also proved impossible to derive a quantitative description of drug responses akin to that presented for receptor-based agents. The very diversity of these drugs precludes any unifying relationship between concentration and effect. Nevertheless, concentration-effect curves similar to those previously discussed are often obtained with these drugs, and general concepts such as potency and efficacy still apply. For the sake of discussion, these drugs are grouped arbitrarily into three categories: chemically reactive agents, physically active agents, and counterfeit biochemical constituents.

### Chemically Reactive Agents

Chemically reactive drugs include a wide variety of compounds, some of which interact with small molecules or ions, whereas others attack proteins and other macromolecules. Gastric antacids and metallic ion chelators are two kinds of drugs that combine with inorganic substances within the body. Of particular importance to dentistry are the systemic and topical fluorides used to increase tooth resistance against dental caries. Also of interest is dimercaprol, a chelating agent capable of forming coordination complexes with mercury and other heavy metals. Drugs affecting macromolecules



**FIG 1-12** Concentration-effect relationships according to the two-state model. In this example, a tonically active process (constitutive activity) is depicted. Full agonists give the maximal ratio of active to inactive receptors ( $R_a/R_i$ ). Notice that what is being plotted is the log concentration of the drug versus the ratio,  $R_a/R_i$ . Partial agonists also increase the ratio, but to a lesser degree. Antagonists bind without disturbing the existing  $R_a/R_i$  ratio, and inverse agonists exert an opposite effect by reducing the  $R_a/R_i$  ratio and inhibiting a normally partially active pathway. In this example, all the drugs are assumed to have the same receptor affinity.

include most germicides and the antineoplastic alkylating agents. Sodium hypochlorite solutions provide antiseptics and facilitate canal debridement during endodontic therapy because they release hypochlorous acid, a potent chemical disrupter of biologic matter. Generally, these compounds can be readily distinguished from drugs whose effects are receptor mediated. With the exception of certain chelating agents, they lack specificity and may individually react with various substances, organic or otherwise. Minor structural modifications also do not usually influence activity of these drugs. Finally, the reactions of these drugs rely heavily on covalent bonding or on strong ionic attachments; they do not usually depend on hydrophobic or weak electrostatic interactions.

### Physically Active Agents

Physically active agents, in contrast, are often useful therapeutically because they are chemically inert and can safely be used for their coligative properties. Magnesium sulfate is an effective cathartic because it is not absorbed from the gastrointestinal tract and exerts an osmotic effect, causing retention of large amounts of water within the intestinal lumen. The colon becomes distended and is stimulated to undergo expulsive contraction. Through a similar osmotic mechanism, mannitol helps reverse cerebral edema in a patient with traumatic brain injury. A totally unrelated physical mechanism is evoked by hydrogen peroxide. Although highly reactive, hydrogen peroxide is useful in wound debridement because of its effervescent action. The release of gas bubbles promotes the physical removal of debris from injured tissues.

The physically active agents generally exhibit a surprising lack of structural specificity. For many agents, the major requirements for activity seem to be a certain pharmacologic inertness coupled with the ability to be administered in high concentrations (compared with most other drugs) without causing undue toxicity.

### Counterfeit Biochemical Constituents

Counterfeit biochemicals are those that are incorporated into specific macromolecules by the cell. They are artificial analogues of natural substrates. The resulting drug effects arise from an altered biologic activity of the affected macromolecules or from their increased susceptibility to destruction. The 2'-deoxycytidine analogue cytarabine is representative of this group. When incorporated into a cell's DNA, cytarabine inhibits the reparative and replicative functions of DNA polymerase. Affected cells may undergo apoptosis or terminal differentiation. Agents of this type are used therapeutically in the treatment of several neoplasias and microbial infections.

## CASE DISCUSSION

Salmeterol is an agonist at  $\beta_2$ -adrenergic receptors. By stimulating these receptors, it causes bronchodilation. Salmeterol is used chronically and has a long duration of action. Rescue inhalers act on the same receptors but are more effective in providing a quick and more pronounced effect than salmeterol. However, repeated administration of a rescue inhaler can cause these receptors to desensitize and downregulate, a mechanism discussed earlier. This results in a reduced ability of the drug to cause bronchodilation, which is one reason there is the warning against overuse of the rescue inhaler. The warning against overuse of salmeterol is based on a similar but less pronounced effect on the  $\beta_2$ -adrenergic receptors. Therefore, a glucocorticosteroid (e.g., fluticasone) is usually given with salmeterol to reduce the risk of a breakthrough asthma attack. Nonetheless, salmeterol administration needs to be given for as limited duration as possible.

## GENERAL REFERENCES

1. Ariëns EJ, Simonis AM, van Rossum JM: Drug-receptor interactions: interaction of one or more drugs with one receptor system. In Ariëns EJ, editor: *Molecular pharmacology: mode of action of biologically active compounds*, New York, 1964, Academic Press.
2. Bhattacharya S, Hall SE, Li H, et al.: Ligand-stabilized conformational states of human  $\beta_2$  adrenergic receptor: insight into G-protein-coupled receptor activation, *Biophys J* 94:2027–2042, 2008.
3. Clark AJ: The reaction between acetyl choline and muscle cells. Part II, *J Physiol* 64:123–143, 1927.
4. Heng BC, Aibel D, Fussenegger M: G Protein-coupled receptors revisited: therapeutic applications inspired by synthetic biology, *Annu Rev Pharmacol Tox* 54:227–249, 2014.
5. IUPHAR/BPS Guide to Pharmacology (contains receptor classifications and nomenclature) (on the web) <http://www.guidetopharmacology.org/> (accessed 2015).
6. Katritch V, Cherezov V, Stevens RC: Diversity and modularity of G protein-coupled receptor structures, *Trends Pharmacol Sci* 33:17–27, 2012.
7. Kenakin T: Principles: receptor theory in pharmacology, *Trends Pharmacol Sci* 25:186–192, 2004.
8. Kobilka BK: Structural insights into adrenergic receptor function and pharmacology, *Trends Pharmacol Sci* 32:213–218, 2011.
9. Rosenbaum DM, Rasmussen SG, Kobilka BK: The structure and function of G protein-coupled receptors, *Nature* 459:356–363, 2009.
10. Urban JD, Clarke WP, von Zastrow M, et al.: Functional selectivity and classical concepts of quantitative pharmacology, *J Pharmacol Exp Ther* 320:1–13, 2007.
11. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW: Drugs for allosteric sites on receptors, *Annu Rev Pharmacol Tox* 54:165–184, 2014.

# Pharmacokinetics: The Absorption, Distribution, and Fate of Drugs\*

Frank J. Dowd

## KEY INFORMATION

- Drugs are able to penetrate membrane barriers by several mechanisms.
- The more lipid-soluble a drug is, the more likely it is to penetrate the lipid environment of membranes.
- Distribution of weak acids and weak bases depends on pH and the  $pK_a$  of drugs.
- Drug transporters play notable roles in the small intestine, liver, kidneys, and capillaries.
- Each route of drug administration has its own absorption characteristics.
- The blood–brain barrier is effective in keeping many drugs out of the brain.
- Drug distribution in saliva reflects plasma concentrations for several drugs.
- The liver is the most important organ for drug metabolism, employing many key enzymes, most notably the cytochrome P450 enzymes.
- Many factors, including drug inhibitors and drug inducers, can affect cytochrome P450 enzymes.
- The kidneys are the most important organs for excreting drugs.
- First-order kinetics refers to a process (e.g., elimination of a drug) in which a constant percentage of drug is eliminated per unit time.
- Zero-order kinetics refers to a process (e.g., elimination of a drug) in which a constant amount of drug is eliminated per unit time.
- Drugs differ from one another in their volumes of distribution, elimination half-times, and clearances.
- Four equations can be used to calculate drug transit in the body: volumes of distribution, half-times, clearance values, and steady-state plasma concentrations (for multiple dosing).

## CASE STUDY

As a result of oral surgery that you performed on your patient, you prescribe acetaminophen plus codeine #3 (300 mg acetaminophen with 30 mg codeine), two tablets initially and one tablet every 4 hours thereafter (6 doses maximum) as needed for pain. Your patient mentions that due to gastric reflux, he also intends to begin using an over-the-counter histamine-2 blocker. He mentions that he has a bottle of Tagamet (cimetidine) with more pills in it from a previous use. Assuming the cimetidine is not out of date, would you offer any advice to your patient based on this information?

We learned in chapter one (Pharmacodynamics), that the magnitude of the effect of a drug is directly related to the concentration of the drug at the relevant receptors. When a drug is administered to a patient, however, several factors contribute to achieving the drug concentration at the receptors. Drug concentrations are rarely static; they increase and decrease as dictated by the processes of absorption, distribution, metabolism, and excretion. This chapter examines these processes (**pharmacokinetics**, Fig. 2-1) and how they influence the passage of drugs through the body.

## PASSAGE OF DRUGS ACROSS MEMBRANES

For a drug to be absorbed, reach its site of action, and eventually be eliminated, it must cross one or more biologic membrane barriers. Because such barriers to drugs behave similarly, the cell membrane can

serve as an example for all. The cell membrane is composed of a bimolecular sheet of lipids (primarily phospholipids and cholesterol) with proteins interspersed throughout and extending beyond the lipid phase of the membrane (Fig. 2-2). The presence of protein molecules spanning the entire thickness of the membrane provides a necessary link between the extracellular environment and the cell interior, which is consistent with the concept that drug activation of a membrane-bound receptor on the external surface of a cell can be directly translated into an intracellular response. Specific transmembrane proteins also provide important pathways for the uptake and extrusion of drugs.

### Passive Diffusion

The passage of drugs across biologic membranes can involve several different mechanisms. Of these, passive diffusion is the most commonly encountered. The defining characteristic of passive diffusion is that the drug moves down its electrochemical gradient when crossing the membrane. The gut epithelial barrier is a good example of how drugs can permeate cell barriers.

### Simple diffusion

One way that hydrophilic drugs may penetrate a cell barrier is by aqueous diffusion, by permeating between epithelial tight junctions or through aqueous pores. This avoids the lipid barrier of the cell membrane, but it is limited by drug size and other restrictions. More commonly, lipophilic drugs will diffuse directly through the lipid barrier of the cell membrane (**lipid diffusion**). The rate of transfer of nonelectrolytes across a membrane is directly proportional to the lipid/water partition coefficient. (The partition coefficient is a measure of the relative solubility of an agent in a fat solvent, such as olive oil or octanol, vs its

\*The author wishes to recognize Dr. John A. Yagiela for his past contributions to this chapter.


solubility in water [Fig. 2-3].) A drug with a high partition coefficient (i.e., a *lipophilic* drug) readily enters the lipid phase of the membrane and passes down its concentration gradient to the aqueous phase on the other side. More molecules are then free to enter the membrane and continue the transfer process. With poorly lipid-soluble compounds, however, only a few molecules enter the membrane per unit of time, and the rate of passage is depressed.

The absence of an ionic charge is one major factor favoring lipid solubility. Conversely, drugs with an ionic charge, such as those containing


a quaternary nitrogen atom, permeate membranes slowly if at all. The term **hydrophobic bonding**, introduced in Chapter 1, refers to the tendency for water-insoluble molecules to be drawn together; this behavior is responsible for the preferential tendency of lipid-soluble drugs to penetrate cell membranes by way of the lipid components. Many other therapeutic agents are weak electrolytes; depending on the pH of their aqueous environment, they can exist in ionized and neutral forms. Because charged molecules penetrate membranes with considerable difficulty, the rate of movement of these drugs is governed by the **partition coefficient** of the neutral species versus the **ionized species**. As illustrated in Figure 2-4, acidic conditions favor the transport of weak acids, and the opposite holds true for basic compounds.

The same concept of water interaction used to explain the aqueous solubility of ions also applies to many nonionic molecules. Although unsubstituted aliphatic and aromatic hydrocarbons have little or no tendency to react with water, affinity for water molecules is not restricted to structures with a formal charge. Organic residues possessing electronegative atoms such as oxygen, nitrogen, and sulfur can interact with water through the formation of hydrogen bonds to provide some degree of aqueous solubility.

Figure 2-3 shows that lipid solubility is not the only factor influencing the simple diffusion of uncharged drugs across cell membranes; molecular size is also important. Water, glycerol, and some other very small molecules permeate much more readily than would be predicted from their respective partition coefficients. Figure 2-3 also shows that some large organic molecules diffuse more slowly than expected, indicating that some degree of water solubility is necessary for the passive diffusion of drugs across membranes. No matter how lipid soluble an agent is, it will never cross a membrane if it cannot first dissolve in the extracellular fluid and be carried to the membrane structure. Benzocaine, an active local anesthetic when applied directly to nerves, is ineffective after injection because its water insolubility precludes significant diffusion away from the administration site and toward its locus of action within the neuronal membrane.



**FIG 2-1** Outline of the major pathways of absorption, distribution, metabolism, and excretion of drugs. Compounds taken orally must pass through the liver before reaching the systemic circulation. When in the bloodstream, agents are distributed throughout the body and come in contact with their respective sites of action. Drugs are filtered by the kidney, only to be reabsorbed if lipid soluble. Metabolism of many drugs occurs primarily in the liver, after which the metabolites are excreted in bile or via urine. Some agents eliminated in the bile are subject to reabsorption and may participate in an enterohepatic cycle.




**FIG 2-2** Cells are surrounded by a plasma membrane composed of a phospholipid bilayer, cholesterol, proteins, and carbohydrates. Modified from VanMeter KC, et al.: *Microbiology for the Healthcare Professional*, St Louis, ed 2, 2016, Mosby.

Similarly, when inside a membrane, a drug with an extremely high partition coefficient may be so soluble in the lipid phase that it has little tendency, despite moderate solubility in water, to diffuse out of the membrane down its concentration gradient. This is commonly called “lipid trapping.”


Simple diffusion across capillary walls warrants special comment. In addition to the transcellular pathway of drug diffusion just described for lipid-soluble agents, an aqueous **paracellular pathway** formed by 10-nm to 15-nm clefts between the endothelial cells of most capillaries permits the aqueous diffusion of water-soluble drugs between the plasma and extracellular space. Hydrophilic molecules up to small proteins in size can use this route; fixed negative charges along the diffusion pathway tend to promote the movement of positively charged macromolecules while restricting movement of those with net negative charges.

### Facilitated diffusion

Water, small electrolytes, and hydrophilic molecules of biologic importance generally move across plasma membranes much more readily than would be predicted by simple diffusion. In these instances,



**FIG 2-3** Relationship between membrane permeability and lipid (olive oil)/water partition coefficient in *Chara certatophylla*. Each circle represents a single nonelectrolyte with a molecular radius as indicated in the key. Small compounds permeate more readily than their partition coefficient would indicate; the reverse is true for large molecules. (Adapted from Collander R: The permeability of plant protoplasts to small molecules, *Physiol Plantarum* 2:300-311, 1949.)



**FIG 2-4** Membrane penetration by weak electrolytes. The nonionic species of drugs ( $HA$ ,  $B$ ) permeate membranes much more efficiently than do the charged forms ( $A^-$ ,  $BH^+$ ). Acidic conditions shift the dissociation curves to the left, favoring the diffusion of weak acids. An increase in pH favors the loss of hydrogen ( $H^+$ ) and the diffusion of weak bases.

transmembrane proteins serve to circumvent the lipid bilayer and facilitate diffusion. The simplest mechanism involves a transmembrane pore (porin), such as aquaporin 1. Discovered in 1991, aquaporin 1 is a 28-kDa polypeptide that forms a 3-Å channel through which water can enter or leave cells. More than 10 variants of aquaporins have been discovered in mammalian tissues and are especially prominent in cells and organs involved with the transcellular movement of water: kidneys, capillaries, secretory glands, red blood cells, choroid plexus, brain glia, eyes, and lungs. Some aquaporins are selective for water only, increasing membrane permeability by a factor of up to 100 times; others permit the passage of glycerol and several other small molecules in addition to water.


The movement of specific ions (e.g.,  $Na^+$ ,  $K^+$ , and  $Ca^{++}$ ) across the cell membrane is facilitated by the presence of transmembrane channels, such as the nicotinic receptor described in Figure 7-4 and the  $Na^+$  channel illustrated in Figure 14-4. The opening of these gated channels (in contrast to porins, which are always open) is regulated by the electric potential across the membrane or by the presence of specific ligands, such as neurotransmitters. When a channel is open, passive diffusion of an ion capable of traversing it depends on the electric potential across the membrane and the chemical gradient of the ion. Boosting the electrochemical gradient by manipulating the voltage across the cell membrane is an effective method of increasing ionic flow. Even in the absence of specific ion channels, the transport of fixed ions and weak electrolytes across tissue barriers can be facilitated by the appropriate use of electric current (as in iontophoresis, discussed subsequently).

Numerous lipid-insoluble substances are shuttled across plasma membranes by forming complexes with specific membrane constituents called **carriers** or **transporters**. Carriers are similar to receptors in many ways; they are proteins, often quite selective about the agents with which they combine, and subject to competitive inhibition. Because the number of transporter molecules is finite, carrier-mediated diffusion can be saturated at high drug concentrations. The GLUT family of glucose transporters is representative of carrier proteins that facilitate the movement of hydrophilic solutes across cell membranes. The initial step in the facilitated diffusion of glucose is its binding to the exposed active site of the transporter protein. This binding sequentially causes an external barrier or gate to close and interior gate to open, after which the glucose is released into the cell. The release of glucose causes the internal gate to close and the external gate to open, re-exposing the active site and completing the cycle.

### Active Transport

**Active transport** is the term given to the carrier-mediated transfer of a drug against its electrochemical gradient. In addition to exhibiting selectivity and saturability, active transport requires the expenditure of energy and may be blocked by inhibitors of cellular metabolism. Active transport permits the efficient absorption of substances vital for cellular function (and certain drugs that resemble them structurally) and the selective elimination of waste products and foreign chemicals, including many drugs. Approximately 2000 genes—7% of the total human genome—code for transporters and associated proteins. Two superfamilies of transporters are of special significance to pharmacokinetics: **ATP-binding cassette (ABC) transporters** and **solute carrier (SLC) transporters**.

ABC transporters hydrolyze adenosine triphosphate (ATP) to provide the energy directly needed for molecular transport and are referred to as **primary active transporters**. The most extensively researched representative is **P-glycoprotein** (“P” for altered permeability). Originally identified in 1976 for its ability to expel numerous antineoplastic drugs from mutated cells that overexpress it,



**FIG 2-5** Two-dimensional topology of P-glycoprotein. Two transmembrane domains (*TMDs*) provide the transport mechanism and are powered by the nucleotide-binding domains (*NBDs*) that hydrolyze ATP. (Adapted from Sarkadi B, Homolya L, Szakács G, et al.: Human multidrug resistance ABCB and ABCG transporters: participation in a chemotherapeutic defense system, *Physiol Rev* 86:1179-1236, 2006.)

P-glycoprotein is a complex 170-kDa glycoprotein with transmembrane domains that form the pump itself and a nucleotide-binding domain that hydrolyzes ATP to power the transport (Fig. 2-5). P-glycoprotein preferentially promotes the cellular extrusion of large (300 to 2000 Da) hydrophobic substances and neutral or positively charged amphiphilic molecules. Transported drugs include numerous anticancer agents (e.g., doxorubicin, vinblastine, and paclitaxel), antiviral compounds (e.g., ritonavir),  $\text{Ca}^{++}$ -channel blockers (e.g., diltiazem), digoxin, antibiotic and antifungal drugs (e.g., erythromycin and ketoconazole), hormones (e.g., testosterone), and immunosuppressants (e.g., cyclosporine).

Drug binding to active transporters occurs within the plasma membrane near the cytoplasmic surface, limiting transport to drugs with good lipid solubility or sufficient length to reach the active site. P-glycoprotein is expressed in various cells, but the highest concentrations are located in intestinal epithelial cells; renal proximal tubular cells; canalicular membranes of hepatocytes; the capillary endothelium of the brain, choroid plexus, testes, and placenta; placental trophoblasts; adrenocortical cells; and stem cells. Other ABC transporters important in pharmacokinetics include the multidrug resistance-associated protein (MRP) family. Collectively, the MRP transporters are also widespread and involved in the vectorial (one-way) movement of drugs and other xenobiotics. In contrast to P-glycoprotein, the MRP transporters pump amphipathic molecules with at least one negative charge. These substrates include bile salts, nucleotide analogues, and conjugates of glutathione, glucuronic acid, and sulfate.

In contrast, SLC transporters do not directly use ATP as an energy source for transport and are referred to as **secondary active transporters**. These transporters require an electrochemical gradient down which solutes can move. The  $\text{Na}^+$  pump ( $\text{Na}^+, \text{K}^+ \text{-ATPase}$ ) a **primary active transport** process, is the main driving force for secondary active transport. By maintaining a large electrochemical gradient for  $\text{Na}^+$  across the plasma membrane, movements of molecules that are energetically coupled to  $\text{Na}^+$  (or another ion with a strong electrochemical potential difference across the membrane) can occur against their own concentration gradients. Secondary active transporters that move the coupled substances in the same direction as the linked ion are termed **cotransporters** or **symporters**. In contrast, **antiporters** or **exchangers** move the coupled substances in the opposite direction. Many SLC transporters (including the GLUT family described previously) allow the transmembrane movement of specific chemicals down their own electrochemical gradients and therefore support facilitated diffusion. In contrast to the ABC transporters, SLC transporters can facilitate bidirectional movement of substrates based on their existing concentrations across the cell membrane.

Organic anion transporters (OATs) and organic anion-transporting polypeptides (OATPs) are important subfamilies of SLC

transporters involved in pharmacokinetics. As a group, they promote the cellular uptake of acidic drugs into the liver, kidney, intestine, lung, and brain, as well as their excretion via the bile and urine. An analogous family of organic cation transporters (OCTs) provides similar handling of positively charged drugs.

### Endocytosis and Exocytosis

The processes of endocytosis and exocytosis are together the most complex methods of drug transfer across a biologic membrane. The term *endocytosis* refers to a series of events in which a substance is engulfed and internalized by the cell. (A similar term, *phagocytosis* or “cell eating,” is a variant of endocytosis associated more with the removal of particulate matter by macrophages than with drug transport.)

Endocytosis usually begins with the binding of a compound to be absorbed, usually a macromolecule, by its receptor on the membrane surface. Several mechanisms exist. A good example is the attachment of low-density lipoprotein (LDL) to its respective receptor. With time, the bound agent–receptor complex is concentrated in an indentation of the membrane called a coated pit. *Clathrin*, a cytoplasmic protein that attaches to the internal surface of the plasma membrane, serves to capture the receptors within the pit while excluding other surface proteins. Internal rearrangement of its structure deepens the pit, forming a coated bud. A second protein, termed *dynamain*, is believed to congregate around the collar of the invaginated bud and initiate separation from the membrane. When released, the vesicle loses its clathrin coat and fuses with a cytoplasmic organelle called the endosome. Some of the captured contents, such as the LDL receptors, are recycled back to the plasma membrane by transport vesicles; the remainder undergo lysosomal processing and release into the cytoplasm.

The complementary process of exocytosis occurs when vesicles, such as those produced by the Golgi apparatus, fuse with the plasma membrane and discharge their contents outside the cell. Exocytosis is the primary method by which cellular products such as regulatory hormones are secreted by the cell. The term *transcytosis* is descriptive of a coupled form of endocytosis and exocytosis leading to the transfer of drug from one epithelial surface of a cell to another.

## ABSORPTION

Absorption refers to the transfer of a drug from its site of administration into the bloodstream. The particular route of administration selected greatly influences the rate and perhaps the extent of drug absorption.

### Oral Ingestion

Oral ingestion was the first, and is still the most commonly used, method for the administration of therapeutic agents. The major advantages of the oral route lie in three areas: convenience, economics, and safety (Table 2-1). The bulk of drug absorption occurs in the small intestine with lesser amounts being absorbed in the stomach. Sudden high blood concentrations are not nearly as likely to be achieved by the ingestion of drugs as they are by parenteral injection. Allergic reactions are also less likely to occur, especially serious reactions. The oral route does have some drawbacks, however. Because self-administration is the rule, patient compliance is required for optimal therapy. Drug absorption is likely to be delayed (on a clinical average of 30 to 60 minutes) and may be incomplete. Metabolic inactivation or complex formation may also occur before the drug has a chance to reach the systemic circulation. These limitations to the oral route translate into an increased variability in patient response (Table 2-1).